SAN ANTONIO--(BUSINESS WIRE)--Acelity, a global wound care and regenerative medicine company, today announced that Nanova™ Therapy System, a new absorbent dressing enhanced with negative pressure for slow-to-heal wounds, is now available in Europe. The disposable hand-activated Nanova™ Therapy Unit can be used up to 30 days with multiple dressings, providing an easy-to-use, cost-effective way for clinicians to continue negative-pressure wound therapy (NPWT) outside the hospital setting.
“Existing NPWT devices can be seen as overly complex for the management of lower acuity wounds, particularly in post-acute settings where the majority of chronic wounds reside,” said Joe Woody, president and CEO, Acelity. “With the addition of the Nanova™ Therapy System, we provide clinicians with a convenient and cost-effective treatment option for these slow-to-heal wounds, while strengthening Acelity’s industry-leading portfolio across the total spectrum of wound acuity and care settings.”
Weighing only 7.2g, the Nanova™ Therapy Unit can be carried in a pocket, will not impede patient mobility, and may enable an earlier return to daily activities. In addition, the dressing’s absorbent layer retains exudate, removing the need for a separate fluid reservoir. The dressing incorporates DermaTac™ Protective Seal Technology, which is unique in providing an effective seal, while enabling easy repositioning of the dressing as required. Importantly, in the community setting, the dressing will continue to absorb exudate even in the absence of negative pressure.
“In our experience, the Nanova™ Therapy System is intuitive to use, which is important because patients can self-manage between clinic visits and, because it is small, lightweight and silent, there is little impact on their lifestyle and normal activity,” said Professor Keith Harding CBE, Medical Director Welsh Wound Innovation Centre. “The Nanova™ System enables the effective application of negative pressure therapy in an outpatient setting, which is a very useful alternative when managing wounds that are not responding to treatment with dressings alone.”
Acelity is focused on changing the practice of medicine with transformative technology and providing innovative healing solutions that restore patient lives. Early clinical experience will be discussed at the European Wound Management Association (EWMA) Congress this week at the ExCel, London, U.K. For more information, please visit www.nanovatherapy.eu.
Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.